Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

The following is a summary of “Patient and physician perspectives on disease burden in chronic spontaneous urticaria,” ...

Remibrutinib results in significant improvement in composite measure of itching and hives after second-generation H1-antihistamine treatment.

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...

Ascilion's products for dermal interstitial fluid sampling will be the focus of six different presentations at the Microneedles 2025 Conference.</ ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase ...

TUESDAY, March 11, 2025 (HealthDay News) -- For patients with symptomatic chronic spontaneous urticaria after treatment with ...